Hard on the heels of an FDA approval for Roche’s Tecentriq and Celgene’s Abraxane for triple-negative breast cancer (TNBC), the regimen has been cleared for early access in the UK. The green light means adult patients with PD-L1 positive, unresect...
Original Article: UK gets early access to Roche’s breast cancer immunotherapy